 - Exclusion criteria includes, congestive heart failure NYHA class III IV or ejection fraction less than 35, poorly controlled hypertension blood pressure 16090, hypercholesterolemia total cholesterol 6.2 mmoll, hypertriglyceridemia triglycerides 4.0 mmoll, poor or excellent control of DM HgA1c 6 or HbA1c 10 respectively, known diabetic retinopathy, age at diagnosis of diabetes less than 25 years, current participation in another clinical trial and contraindications to glitazones therapy, including renal creatinine 200 micromol L or hepatic ALT 2.5 times the upper limit of normal impairment and or known intolerance to glitazones. Patients must be stable on medications that affect endothelial function for more than one month. This includes ACE-inhibitors, angiotensin receptor blockers, statins, calcium channel blockers, hormone replacement therapy and anti-oxidant vitamins, including folates. Patients on insulin will be excluded. Patients in whom it is felt that attainment of better glucose control is required within 3 months will also be excluded. Patients with stable coronary disease will be eligible for the study as long as they are one month post myocardial infarction, percutaneous intervention or bypass surgery. 